

## EXHIBIT A

BEST AVAILABLE COPY



# PHYSICIANS' DESK REFERENCE<sup>®</sup>

**Medical Consultant**

Ronald Arky, MD, Charles S. Davidson Professor of Medicine and Master, Francis Weld Peabody Society, Harvard Medical School

**Executive Vice President, Directory Services: Paul A. Konowitch**

Vice President of Product Management: Stephen B. Greenberg  
 Product Managers: Cy S. Caine, Mark A. Friedman  
 National Sales Manager: Dilshan N. Bersamian  
 Senior Account Manager: Anthony Sorice  
 Account Managers:  
 Donald V. Brucoleri  
 Lawrence C. Kearny  
 Jeffrey M. Keller  
 Jeffrey F. Pfohl  
 P. Anthony Pinomeau  
 Trade Sales Manager: Robin B. Barnett  
 Trade Sales Account Executive: Bill Gaffney  
 Direct Marketing Manager: Robert W. Chapman  
 Marketing Communications Manager: Maryann Maiorgo  
 Director, Professional Support Services: Mukesh Mehta, RPh  
 Drug Information Specialists: Thomas Ruming, RPh, Marion Gray, RPh  
 Editor, Special Projects: David W. Shifrin

Vice President of Production: David A. Piller  
 Vice Presidents, Contract Services/Fulfillment: Steven R. Andreazza  
 Contracts and Support Services Director: Marjorie A. Duffy  
 Manager, Database Administration: Lynne Handler  
 Director of Production, Annuals: Carrie Williams  
 Manager of Production, Annuals: Kimberly Hiller-Vives  
 Senior Production Coordinators: Amy B. Brooks, Dawn B. McCall  
 Production Coordinator: Mary Ellen R. Braun  
 Index/Format Manager: Jeffrey D. Schaefer  
 Senior Format Editor: Gregory J. Westley  
 Assistant Index Editor: Elton C. Izdik  
 Art Associate: Joan K. Akerlind  
 Electronic Publishing Coordinator: Joanne M. Pearson  
 Senior Digital Imaging Coordinator: Shawn W. Cahill  
 Digital Imaging Coordinator: Frank J. McElroy, III

**Copyright © 1997 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742.** All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Nonprescription Drugs, PDR For Ophthalmologists, Pocket PDR®, and The PDR® Family Guide to Prescription Drugs are registered trademarks used herein under license. PDR Guide to Drug Interactions, Side Effects, Indications, Contraindications™, PDR® Generics™, PDR® Medical Dictionary™, PDR® Nurse's Handbook™, PDR® Nurses' Dictionary™, The PDR® Family Guide to Women's Health and Prescription Drugs™, The PDR® Family Guide to Nutrition and Health™, PDR® Electronic Library™, and PDR® Drug REAX™ are trademarks used herein under license.

Officers of Medical Economics Company: President and Chief Executive Officer: Curtis B. Allen; Vice President, Human Resources: Pamela M. Blasch; Vice President, Finance, and Chief Financial Officer: Thomas W. Ehndt; Executive Vice President: Richard F. Kilman; Executive Vice President, Directory Services: Paul A. Konowitch; Executive Vice President, Magazine Publishing: Thomas F. Rice; Senior Vice President, Operations: John R. Ward; Vice President, Information Services, and Chief Information Officer: Edward J. Zecchi

ISBN: 1-56963-201-2

# EXHIBIT A

**SSD/PHYSICIANS' DESK REFERENCE®**
**Ciba Self-Medication, Inc.—Cont.**

delivery system of SLOW FE is designed to maximize the release of ferrous sulfate in the duodenum and the jejunum where it is best tolerated and absorbed. SLOW FE has been clinically shown to be associated with a lower incidence of constipation, diarrhea and abdominal discomfort when compared to an immediate release iron tablet<sup>1</sup> and a leading sustained release iron capsule.<sup>2</sup>

**FORMULA**

Each tablet contains: Active Ingredient: 160 mg dried ferrous sulfate USP, equivalent to 50 mg elemental iron. Inactive ingredients: cetearyl alcohol, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyacrylic acid 80, talc, titanium dioxide, yellow iron oxide, FD&C blue #2 aluminum lake.

**DOSEAGE**

**ADULTS**—one or two tablets daily or as recommended by a physician. A maximum of four tablets daily may be taken. **CHILDREN**—one tablet daily. Tablets must be swallowed whole.

**WARNING**

The treatment of any anemic condition should be under the advice and supervision of a physician. As oral iron products interfere with absorption of oral tetracycline antibiotics, these products should not be taken within two hours of each other. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.

Keep this and all drugs out of the reach of children. Close bottles tightly. Contains iron which can be harmful or fatal to children in large doses. In case of accidental overdose, seek professional assistance or contact a poison control center immediately.

**Tamper-Evident Packaging**
**HOW SUPPLIED**

Blister Packages of 30 and 60, and bottles of 100 supplied in Child-Resistant packaging.

Do not store above 30°C (86°F). Protect from moisture.

**REFERENCES**

- Brock C et al. Adverse effects of iron supplementation: A comparative trial of a wax-matrix iron preparation and conventional ferrrous sulfate tablets. *Clin Ther.* 1985; 7:1-6.
- Brock C, Curry H. Comparative incidence of side effects of a wax-matrix and a sustained-release iron preparation. *Clin Ther.* 1985;14:492-496.

Shown in Product Identification Guide, page 308

**SLOW FE® WITH FOLIC ACID OTC  
(Slow Release Iron - Folic Acid)**
**DESCRIPTION**

Slow Fe + Folic Acid delivers 50 mg. elemental iron (160 mg. dried ferrous sulfate) using the unique wax matrix delivery system described above (for SLOW FE® Slow Release Iron Tablets) plus 400 mcg. folic acid.

Provides women of childbearing potential with the daily target level of folic acid to reduce the risk of neural tube birth defects. These birth defects are rare, but serious, and occur within 28 days of conception, often before a woman knows she's pregnant.

**FORMULA**

Each tablet contains: Active Ingredients: 160 mg. dried ferrous sulfate, USP (equivalent to 50 mg. elemental iron) and 400 mcg. folic acid. Inactive Ingredients: cetearyl alcohol, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyacrylic acid 80, talc, titanium dioxide, yellow iron oxide.

**DOSEAGE**

**ADULTS**—One or two tablets once a day or as recommended by a physician. A maximum of two tablets daily may be taken. **CHILDREN UNDER 12**—Consult a physician. Tablets must be swallowed whole.

**WARNING**

The treatment of any anemic condition should be under the advice and supervision of a physician. As oral iron products interfere with absorption of oral tetracycline antibiotics, these products should not be taken within two hours of each other. Intake of folic acid from all sources should be limited to 1000 mcg. per day to prevent the masking of Vitamin B<sub>12</sub> deficiency. Should you become pregnant while using this product, consult a physician as soon as possible about good prenatal care and the continued use of this product. If you are already pregnant or nursing a baby, seek the advice of a health care professional before using this product. **KEEP THIS PRODUCT AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.**

Contains iron, which can be harmful or fatal to children in large doses. In case of accidental overdose, contact a physician or a poison control center immediately.

**HOW SUPPLIED**

Blister packages of 20 supplied in Child-Resistant packaging. Do not store above 30°C (86°F). Protect from moisture.

**CHILD-RESISTANT**  
Blister packaged for your protection. Do not use if individual seals are broken.

Distributed by: Ciba Self-Medication, Inc.  
Woodbridge, NJ 07095

Tablets made in Great Britain

© 1994 Ciba Self-Medication, Inc.  
Shown in Product Identification Guide, page 308

**TRANSDERM SCOP®**

(transdermal scope)

scopolamine

Transdermal Therapeutic System

Programmed delivery *in vivo* of 0.5 mg of scopolamine over 3 days

B

**Prescribing Information**
**DESCRIPTION**

The Transderm Scop patch is a circular flat disc designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Clinical evaluation has demonstrated that the patch provides effective antiemetic and antinauseant actions when tested against motion-sickness stimuli in adults. The Transderm Scop patch is a film 0.2 mm thick and 2.0 cm<sup>2</sup>, with four layers. Proceeding from the visible surface towards the surface attached to the skin, these layers are: (1) backing layer of tan-colored, aluminum, polyester film; (2) a drug reservoir of scopolamine, mineral oil, and polyisobutylene; (3) a micro-porous polypropylene membrane that controls the rate of delivery of scopolamine from the patch to the skin surface; and (4) an adhesive formulation of cedar oil, polyisobutylene, and scopolamine. A protective peel strip of siliconized polyester, which covers the adhesive layer, is removed before the patch is used. The inactive components, mineral oil (12.4 mg) and polyisobutylene (11.4 mg), are not released from the system.

Cross section of the patch:



**Release-Rate Concept:** The Transderm Scop patch contains 1.5 mg of scopolamine. The patch is programmed to deliver 0.5 mg of scopolamine at an approximately constant rate to the systemic circulation over the 3-day lifetime of the patch. An initial priming dose of scopolamine, released from the adhesive layer of the patch, saturates the skin binding sites and rapidly brings the plasma concentration of scopolamine to the required steady-state level. A continuous controlled release of scopolamine, which flows from the drug reservoir through the rate-controlling membrane, maintains the plasma level constant.

**CLINICAL PHARMACOLOGY**

The sole active agent of Transderm Scop is scopolamine, a belladonna alkaloid with well-known pharmacological properties. The drug has a long history of oral and parenteral use for central anticholinergic activity, including prophylaxis of motion sickness. The mechanism of action of scopolamine in the central nervous system (CNS) is not definitely known but may include anticholinergic effects. The ability of scopolamine to prevent motion-induced nausea is believed to be associated with inhibition of vestibular input to the CNS, which results in inhibition of the vomiting reflex. In addition, scopolamine may have a direct action on the vomiting center within the reticular formation of the brain stem. Applied to the postauricular skin, Transderm Scop provides a gradual release of scopolamine from an adhesive matrix of mineral oil and polyisobutylene.

**INDICATIONS AND USAGE**

Transderm Scop is indicated for prevention of nausea and vomiting associated with motion sickness in adults. The patch should be applied only to skin in the postauricular area.

**Clinical Results:** Transderm Scop provides antiemetic protection within several hours following application of the patch behind the ear. In 183 adult subjects of different racial origins who participated in clinical efficacy studies at sea or in a controlled motion environment, there was a 76% reduc-

tion in the incidence of motion-induced nausea and vomiting. Transderm Scop provided significantly greater protection than that obtained with oral dimenhydrinate.

**CONTRAINDICATIONS**

Transderm Scop should not be used in patients with known hypersensitivity to scopolamine or any of the components of the adhesive matrix making up the therapeutic system, or in patients with glaucoma.

**WARNINGS**

Transderm Scop should not be used in children and should be used with special caution in the elderly. See PRECAUTIONS.

Since drowsiness, disorientation, and confusion may occur with the use of scopolamine, patients should be warned of the possibility and cautioned against engaging in activities that require mental alertness, such as driving a motor vehicle or operating dangerous machinery. Potentially alarming idiosyncratic reactions may occur with ordinary therapeutic doses of scopolamine.

**PRECAUTIONS**
**General**

Scopolamine should be used with caution in patients with pyloric obstruction, or urinary bladder neck obstruction. Caution should be exercised when administering an anticholinergic or antimuscarinic drug to patients suspected of having intestinal obstruction.

Transderm Scop should be used with special caution in the elderly or in individuals with impaired metabolic, liver, or kidney functions, because of the increased likelihood of CNS effects.

**Information for Patients**

Since scopolamine can cause temporary dilation of the pupil and blurred vision if it comes in contact with the eyes, patients should be strongly advised to wash their hands thoroughly with soap and water immediately after handling the patch.

Patients should be advised to remove the patch immediately and contact a physician in the unlikely event that they experience symptoms of acute narrow-angle glaucoma (pain in and redness of the eyes accompanied by dilated pupils). Patients should be warned against driving a motor vehicle or operating dangerous machinery. A patient brochure is available.

**Drug Interactions**

Scopolamine should be used with care in patients taking drugs including alcohol, capable of causing CNS effects. Special attention should be given to drugs having anticholinergic properties, e.g., belladonna alkaloids, antihistamines (including meclizine), and antidepressants.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term studies in animals have been performed to evaluate carcinogenic potential. Fertility studies were performed in female rats and revealed no evidence of impairment of fertility or harm to the fetus due to scopolamine hydrobromide administered by daily subcutaneous injection. In the highest-dose group (plasma level approximately 600 times the level achieved in humans using a transdermal system), reduced maternal body weights were observed.

**Pregnancy Category C**

Teratogenic studies were performed in pregnant rats and rabbits with scopolamine hydrobromide administered by daily intravenous injection. No adverse effects were recorded in the rats. In the rabbits, the highest dose (plasma level approximately 100 times the level achieved in humans using a transdermal system) of drug administered had a marginal embryotoxic effect. Transderm Scop should be used during pregnancy only if the anticipated benefit justifies the potential risk to the fetus.

**Nursing Mothers**

It is not known whether scopolamine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Transderm Scop is administered to a nursing woman.

**Pediatric Use**

Children are particularly susceptible to the side effects of belladonna alkaloids. Transderm Scop should not be used in children because it is not known whether the patch will release an amount of scopolamine that could produce serious adverse effects in children.

**ADVERSE REACTIONS**

The most frequent adverse reaction to Transderm Scop is dryness of the mouth. This occurs in about two thirds of patients on drug. A less frequent adverse reaction is drowsiness, which occurs in less than one sixth of patients on drug. Transient impairment of eye accommodation, including blurred vision and dilation of the pupils, is also observed. The following adverse reactions have also been reported on infrequent occasions during the use of Transderm Scop: disorientation; memory disturbances; dizziness; restlessness; hallucinations; confusion; difficulty urinating; rashes and erythema; acute narrow-angle glaucoma; and dry, itchy, or red eyes.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.